1. Signaling Pathways
  2. Anti-infection
  3. HBV

HBV

Hepatitis B virus

HBV (Hepatitis B virus), abbreviated HBV, is a species of the genus Orthohepadnavirus, which is likewise a part of the Hepadnaviridae family of viruses. HBV causes the disease hepatitis B. The hepatitis B virus is classified as the type species of the Orthohepadnavirus, which contains three other species: the Ground squirrel hepatitis virus, Woodchuck hepatitis virus, and theWoolly monkey hepatitis B virus. The genus is classified as part of the Hepadnaviridae family. HBV is divided into four major serotypes (adr, adw, ayr, ayw) based on antigenic epitopes present on its envelope proteins, and into eight genotypes (A–H) according to overall nucleotide sequence variation of the genome. The genotypes have a distinct geographical distribution and are used in tracing the evolution and transmission of the virus. Differences between genotypes affect the disease severity, course and likelihood of complications, and response to treatment and possibly vaccination.

Cat. No. Product Name Effect Purity Chemical Structure
  • HY-W754691
    Glaziovine
    Inhibitor
    Glaziovine is an antiviral agent found in Hypserpa nitida. Glaziovine exhibits significant inhibitory activity against HBV, capable of suppressing hepatitis B virus surface antigen (HBsAg) secretion in Hep G2.2.15 cells transfected with HBV, with an IC50 of 8 nM.
    Glaziovine
  • HY-144047
    HBV-IN-16
    Inhibitor
    HBV-IN-16 is a potent inhibitor of covalently closed circular DNA (cccDNA). cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-16 is a quinoline derivative. HBV-IN-16 has the potential for the research of HBV infection (extracted from patent WO2019121357A1, compound 1).
    HBV-IN-16
  • HY-146011
    HBV-IN-21
    Inhibitor
    HBV-IN-21 (Compound II-8b) is an HBV DNA replication inhibitor with an IC50 of 2.2 µM. HBV-IN-21 can interact HBV 4 capsid protein with good affinity (KD = 60.0 μM).
    HBV-IN-21
  • HY-144322
    HBV-IN-18
    Modulator
    HBV-IN-18 (Compound 3) is an HBV capsid assembly modulator (CpAM) with an EC50 of 2790 nM.
    HBV-IN-18
  • HY-B0017S
    Telbivudine-d4
    Inhibitor
    Telbivudine-d4 is deuterium labeled Telbivudine. Telbivudine (Epavudine), an orally active thymidine nucleoside analog, is a potent antiviral inhibitor of hepatitis B virus (HBV) replication.
    Telbivudine-d<sub>4</sub>
  • HY-W676876
    Oxynitidine
    Inhibitor
    Oxynitidine is an HBV inhibitor (ID50=30.8 µg/mL), which can effectively inhibit the DNA replication activity of HBV. Oxynitidine can be used in the study of viral infections.
    Oxynitidine
  • HY-163580
    HBV/HDV-IN-3
    Inhibitor
    HBV/HDV-IN-3 (Compd 1) is a dual HBV and HDV inhibitor, with an EC50 of <50 nM against HBV.
    HBV/HDV-IN-3
  • HY-10545
    Taribavirin
    Inhibitor
    Taribavirin is an orally active inosine monophosphate dehydrogenase inhibitor, has activity against a wide range of viruses, especially the hepatitis C virus and influenza virus. Taribavirin, is a ribavirin proagent, is designed to concentrate within the liver to target HCV-infected hepatocytes while minimizing distribution within red blood cells (RBCs) and the development of hemolytic anemia.
    Taribavirin
  • HY-155547
    HBV-IN-34
    Inhibitor
    HBV-IN-34 (compound 17i) is a potent HBsAg production inhibitor. HBV-IN-34 exhibits excellent in vitro anti-HBV potency, with an EC50 of 0.018 μM and 0.044 μM for HBV DNA and HBsAg, respectively.
    HBV-IN-34
  • HY-N11792
    Pedunculosumoside F
    Control
    Pedunculosumoside F is a homoflavonoid glucoside. Pedunculosumoside F can be isolated from Ophioglossum pedunculosum. Pedunculosumoside F has cytotoxicity against HepG2 22.15 cells with CC50 value of 56.7 μM without anti-HBV activity. While its analogs block HBsAg secretion in HBV-infected HepG2 2.2.15 cells.
    Pedunculosumoside F
  • HY-B1826S2
    Adefovir-d4
    Inhibitor 98.69%
    Adefovir-d4 is the deuterium labeled Adefovir. Adefovir (GS-0393) is an adenosine monophosphate analog antiviral agent that after intracellular conversion to Adefovir diphosphate inhibits HBV DNA polymerase. Adefovir has an IC50 of 0.7 μM against HBV in the HepG2.2.15 cell line. Adefovir has good antiviral activity against several viruses, including HBV and herpesviruses.
    Adefovir-d<sub>4</sub>
  • HY-B0150A
    Nicotinamide Hydrochloride
    Inhibitor
    Nicotinamide Hydrochloride is a form of vitamin B3 or niacin. Nicotinamide Hydrochloride inhibits SIRT2 activity (IC50: 2 μM). Nicotinamide Hydrochloride also inhibits SIRT1. Nicotinamide Hydrochloride increases cellular NAD+, ATP, ROS levels. Nicotinamide Hydrochloride inhibits tumor growth and improves survival. Nicotinamide Hydrochloride also has anti-HBV activity.
    Nicotinamide Hydrochloride
  • HY-B1067R
    Antazoline hydrochloride (Standard)
    Inhibitor
    Antazoline (hydrochloride) (Standard) is the analytical standard of Antazoline (hydrochloride). This product is intended for research and analytical applications. Antazoline hydrochloride is a histamine H1 receptor antagonist with anticholinergic and antiviral properties. Antazoline hydrochloride can prevent histamine from acting on target cells through a reversible competition effect on histamine receptor sites of these cells. Antazoline hydrochloride can exert an antiallegic effect and prevent the occurrence of physiological reactions from the effect of blocking as well as inhibiting H1 receptor. Antazoline hydrochloride can effectively reduce HBV DNA in the extracellular supernatant in a dose-dependent manner, with EC50 of 2.910 μmol/L in HepAD38 cells. Antazoline hydrochloride also has a significant inhibitory effect on HBV DNA in the extracellular supernatant of Huh7 cells (EC50 = 2.349 μmol/L). Antazoline hydrochloride has anti-arrhythmic effect in acute myocardial infarctions. Antazoline hydrochloride can be studied in research for cardiovascular diseases, and HBV.
    Antazoline hydrochloride (Standard)
  • HY-145055
    HBV-IN-11
    Inhibitor
    HBV-IN-11 is a potent HBsAg secretion inhibitor with an EC50 of 0.46 µM (From patent WO2018085619A1, example 28).
    HBV-IN-11
  • HY-148768
    AB-506
    Inhibitor
    AB-506 is an orally active inhibitor of HBV replication targeting the viral core protein. AB-506 can bind to HBV core protein, accelerate capsid assembly and inhibit HBV pgRNA encapsidation. AB-506 can be used in chronic hepatitis B (CHB) research.
    AB-506
  • HY-147255A
    (S)-Canocapavir
    Control
    (S)-Canocapavir is the isomer of Canocapavir (HY-147255A). Canocapavir (ZM-H1505R) has orally antiviral activity. Canocapavir is a HBV capsid inhibitor that can be used in the research of Chronic hepatitis B.
    (S)-Canocapavir
  • HY-151134
    HBV-IN-25
    Inhibitor
    HBV-IN-25 is a good potency, orally active novel HBV cccDNA reducer. HBV-IN-25 has anti-HBeAg potency and anti-HBV activity with IC50 values of 0.58 μM and 1.15 μM, respectively. HBV-IN-25 has good aqueous solubility (LYSA>452 μg/mL) and good PK property with no cellular toxicity.
    HBV-IN-25
  • HY-148780
    HBV-IN-29
    Inhibitor
    HBV-IN-29 (ex8), a flavone derivative, is a potent covalently closed circular DNA (cccDNA) inhibitor. cccDNA serves as the template for viral RNA transcription and subsequent viral DNA generation. HBV-IN-29 has the potential for the research of HBV infection.
    HBV-IN-29
  • HY-N1323
    Sanggenol P
    Inhibitor
    Sanggenol P, a flavonoid, shows anti-HBV activity on HepG2.2.15 cell line in vitro.
    Sanggenol P
  • HY-B0955R
    Oxethazaine (Standard)
    Inhibitor
    Oxethazaine (Standard) is the analytical standard of Oxethazaine. This product is intended for research and analytical applications. Oxethazaine (Oxetacaine), a precursor of phentermine acidic, is an acid-resistent and orally active analgesic agent. Oxethazaine (Oxetacaine) has the potential for the relief of pain associated with peptic ulcer disease or esophagitis.
    Oxethazaine (Standard)
Cat. No. Product Name / Synonyms Application Reactivity